Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evogene Ltd. - Ordinary Shares (NQ:EVGN)

0.2801 +0.0091 (+3.36%)
Delayed Quote Updated: 12:02 PM EST, Nov 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evogene Ltd. - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
Earnings Scheduled For March 6, 2025 ↗
 
Via Benzinga
News headline image
A Glimpse of Evogene's Earnings Potential ↗
 
Via Benzinga
News headline image
Evogene Earnings Preview ↗
 
Via Benzinga
News headline image
Recap: Evogene Q3 Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 21, 2024 ↗
 
Via Benzinga
News headline image
EVGN Stock Earnings: Evogene Misses EPS, Beats Revenue for Q2 2024 ↗
EVGN stock results show that Evogene missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
EVGN Stock Earnings: Evogene Beats EPS, Beats Revenue for Q1 2024 ↗
EVGN stock results show that Evogene beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
EVGN Stock Earnings: Evogene Beats EPS, Misses Revenue for Q4 2023 ↗
EVGN stock results show that Evogene beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Israeli Company Reports Record 2023 Revenue, Wants To Transition Cannabis Operations To 'Third Party' ↗
Evogene Ltd. released its fourth-quarter and full-year 2023 financial results, showing a 237% revenue increase for the year. Despite a 12% revenue decrease in Q4, the Israeli cannabis company reported... 
Via Benzinga
Topics Cannabis
News headline image
A Preview Of Evogene's Earnings ↗
 
Via Benzinga
News headline image
Lake Street Maintains Buy Rating for Evogene: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 7, 2024 ↗
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
News headline image
Earnings Outlook For Evogene ↗
 
Via Benzinga
News headline image
Israeli Cannabis Company Reports Strong Q3 Despite Geopolitical Challenges ↗
Evogene reports a strong Q3 with $3.8M revenue and significant gross profit growth, showcasing resilience and innovation in cannabis tech. 
Via Benzinga
Topics Cannabis
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 2, 2023 ↗
 
Via Benzinga
News headline image
Why Evogene Shares Are Moving ↗
Evogene Ltd (NASDAQ: EVGN) shares are trading lower by 5.9% to $0.63 Thursday morning after the company received a letter from the Nasdaq indicating that the company is not in compliance with the... 
Via Benzinga
News headline image
Israeli Cannabis Co. Reports Solid Q2 Performance, Nearing Growth Targets ↗
Cannabis company Evogene Ltd. 
Via Benzinga
Topics Cannabis
News headline image
Evogene's Casterra Gets $2.2M Orders To Supply Castor Seeds ↗
Evogene Ltd. (NASDAQ: EVGN) said its unit Casterra Ag Ltd. 
Via Benzinga
News headline image
TalkMarkets Announces Company Spotlight Featuring Evogene ↗
TalkMarkets.com announces a company spotlight series featuring Evogene (NASDAQ: EVGN), an agri-tech and bio-tech company with a computational predictive biological platform technology. 
Via Talk Markets
News headline image
Evogene: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived... 
Via Benzinga
News headline image
Why Evogene Stock Is Tanking Today ↗
Evogene Ltd. (NASDAQ: EVGN) (TASE:EVGN) shares were trading 20% lower at $1.12 per share at the time of writing Monday morning. 
Via Benzinga
News headline image
Why Aehr Test Systems Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
Gainers Ainos, Inc. (NASDAQ: AIMD) shares surged 108.2% to $1.52 in pre-market trading after gaining around 7% on Thursday. 
Via Benzinga
TalkMarkets Announces Company Spotlight Featuring Evogene
TalkMarkets.com announces a company spotlight series featuring Evogene (NASDAQ: EVGN), an agri-tech (agricultural technology) and bio-tech company with a computational predictive biological platform... 
Via TheNewswire.com
News headline image
TalkMarkets Announces Company Spotlight Featuring Evogene
TalkMarkets.com announces a company spotlight series featuring Evogene (NASDAQ: EVGN), an agri-tech and bio-tech company with a computational predictive biological platform technology. 
Via News Direct
News headline image
Evogene - A Company With Valuable Assets Trading At Zero Enterprise Value ↗
From a sum-of-parts perspective, Evogene is likely worth many multiples of its market valuation today, even without ascribing any value to Evogene’s technology. 
Via Talk Markets
News headline image
Why ToughBuilt Industries Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares jumped 209.5% to $2.29 after the company signed a Letter of Intention with UAE-Based e-script medicine management company Pharmak... 
Via Benzinga
News headline image
Why Evogene (EVGN) Stock Is Trading Higher ↗
Evogene Ltd (NASDAQ: EVGN) shares are trading higher by 13.72% to $0.83 Wednesday morning after the company announced its subsidiary, Casterra, signed a framework agreement with an oil & gas company to... 
Via Benzinga
News headline image
Tryp Submits IND Application To FDA For Clinical Trial Of Psilocybin-Assisted Psychotherapy In Patients With IBS ↗
Tryp Therapeutics, Inc. (OTCQB: TRYPF) (CSE:TRYP) has submitted an Investigational New Drug application to the U.S. 
Via Benzinga
News headline image
Evogene Q1 Revenue Grows 170% YoY, Here Are The Details ↗
Evogene Ltd. (NASDAQ: EVGN) (TASE:EVGN) released its financial results for the first quarter period ending March 31, 2023, revealing revenues of $641,000, an increase of 170% compared to $237,000 in... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.